Skip to content
PICO Portalanswers from OpenAlex

First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer

PaperCitations, authors & open-access status

First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer is a paper indexed in PICO Portal from OpenAlex.

How many citations does First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer have?

PICO Portalcitation count

First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer has 70 citations in the OpenAlex counts PICO Portal stores.

When was First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer published?

PICO Portalyear

First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer has 2025 year in the PICO Portal index.

What is the open-access status of First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer?

PICO Portaloa status

First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer has closed oa status in the PICO Portal index.

What is the DOI of First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer?

PICO Portaldoi

The DOI for First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer is on the source record.

What is the PMID of First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer?

PICO Portalpmid

The PMID for First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer is on the source record.

What is the OpenAlex record for First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer?

PICO Portalopenalex

The OpenAlex for First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial